Literature DB >> 32611587

Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.

Shaun Griffin1.   

Abstract

Entities:  

Year:  2020        PMID: 32611587     DOI: 10.1136/bmj.m2650

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  11 in total

Review 1.  Medication use during COVID-19: Review of recent evidence.

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

Review 2. 

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

3.  Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.

Authors:  Giustina De Silvestro; Giorgio Gandini; Francesco Fiorin; Piero Marson; Ersilia Barbone; Andrea Frigato; Gianluca Gessoni; Arianna Veronesi; Monia Pacenti; Monica Castelli; Marianna Rinaldi; Monica Rizzi; Francesca Stefani; Giovanni Roveroni
Journal:  Transfus Apher Sci       Date:  2021-05-07       Impact factor: 1.764

Review 4.  Science's Response to CoVID-19.

Authors:  Marcus J C Long; Yimon Aye
Journal:  ChemMedChem       Date:  2021-06-22       Impact factor: 3.540

Review 5.  Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.

Authors:  Paola Magro; Isabella Zanella; Marta Pescarolo; Francesco Castelli; Eugenia Quiros-Roldan
Journal:  Biomed J       Date:  2020-11-10       Impact factor: 4.910

Review 6.  Current and Future Direct-Acting Antivirals Against COVID-19.

Authors:  Shiu-Wan Chan
Journal:  Front Microbiol       Date:  2020-11-12       Impact factor: 5.640

Review 7.  Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.

Authors:  Ali J Marian
Journal:  Cardiovasc Pathol       Date:  2020-09-02       Impact factor: 2.185

8.  A Systematic Review of COVID-19 and Kidney Transplantation.

Authors:  Viyaasan Mahalingasivam; Alison Craik; Laurie A Tomlinson; Long Ge; Liangying Hou; Qi Wang; Kehu Yang; Damian G Fogarty; Ciara Keenan
Journal:  Kidney Int Rep       Date:  2020-11-03

9.  CSF3 Is a Potential Drug Target for the Treatment of COVID-19.

Authors:  Chao Fang; Jie Mei; Huixiang Tian; Yu-Ligh Liou; Dingchao Rong; Wei Zhang; Qianjin Liao; Nayiyuan Wu
Journal:  Front Physiol       Date:  2021-01-22       Impact factor: 4.566

10.  Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019.

Authors:  Jiaxing Zhang; Yiling Lu; Joey Sum-Wing Kwong; Xiaosi Li; Wenyi Zheng; Rui He
Journal:  Front Pharmacol       Date:  2020-08-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.